Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens

Soumi Gupta, Johan Vingerhoets, Signe Fransen, Lotke Tambuyzer, Hilde Azijn, Arne Frantzell, Roger Paredes, Eoin Coakley, Steven Nijs, Bonaventura Clotet, Christos J. Petropoulos, Jonathan Schapiro, Wei Huang, Gaston Picchio

Research output: Contribution to journalArticleResearchpeer-review

25 Citations (Scopus)

Abstract

Connection domain mutations (CDMs) in HIV-1 reverse transcriptase (RT) alter susceptibility to some nucleoside/nonnucleoside RT inhibitors (NRTIs/NNRTIs). Their effects on susceptibility and virologic responses to etravirine were analyzed. Seventeen CDMs were evaluated: L283I, E312Q, G333D, G333E, G335C, G335D, N348I, A360I, A360T, A360V, V365I, T369I, A371V, A376S, I393L, E399D, and E399G. CDM prevalence and effects on virologic responses were analyzed retrospectively using clinical data. The effects on etravirine susceptibility were assessed in clinical samples and confirmed using site-directed mutants. The most prevalent CDMs (>10%) were A371V, E399D, A376S, N348I, A360T, G333E, and L283I. CDM presence was positively correlated with thymidine analogue-associated mutations, but not with NNRTI resistance-associated mutations (RAMs). The presence or number of CDMs did not significantly reduce etravirine susceptibility, although small reductions were seen in samples with G333D, N348I, A360V, T369I, and A376S. N348I, E399G, and N348I/T369I were associated with reduced etravirine susceptibility when present with K103N, L100I, or Y181C. N348I or T369I was associated with reduced etravirine susceptibility when present with K101P or K103R/V179D. Virologic responses to an etravirine-containing regimen were slightly diminished when G333D, G335D, or A376S was present, but this was not confirmed in subgroups with higher baseline resistance or without etravirine RAMs. CDMs alone do not confer substantial reductions in etravirine susceptibility but can further reduce etravirine susceptibility in combination with certain NNRTI mutations. Since virologic responses to etravirine were not affected by CDMs, the clinical impacts of these mutations on etravirine susceptibility appear to be minimal. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Original languageEnglish
Pages (from-to)2872-2879
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number6
DOIs
Publication statusPublished - 1 Jun 2011

Fingerprint Dive into the research topics of 'Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens'. Together they form a unique fingerprint.

  • Cite this

    Gupta, S., Vingerhoets, J., Fransen, S., Tambuyzer, L., Azijn, H., Frantzell, A., Paredes, R., Coakley, E., Nijs, S., Clotet, B., Petropoulos, C. J., Schapiro, J., Huang, W., & Picchio, G. (2011). Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrobial Agents and Chemotherapy, 55(6), 2872-2879. https://doi.org/10.1128/AAC.01695-10